Galecto Reports First Quarter 2025 Operating and Financial Results
Rhea-AI Summary
Galecto (NASDAQ: GLTO) reported its Q1 2025 financial results and provided updates on its drug development programs. The company continues to advance GB3226, its dual ENL-YEATS and FLT3 inhibitor for acute myeloid leukemia (AML), with IND submission planned for Q1 2026. Preclinical data shows improved efficacy compared to existing treatments.
Financial highlights include:
- Cash position of $11.9 million as of March 31, 2025
- R&D expenses decreased to $0.7 million from $2.5 million year-over-year
- G&A expenses reduced to $1.9 million from $3.3 million year-over-year
- Net loss of $2.5 million ($1.92 per share) compared to $5.5 million ($5.05 per share) in Q1 2024
Positive
- Net loss decreased significantly to $2.5 million from $5.5 million year-over-year
- Operating expenses reduced substantially with R&D costs down by $1.8 million and G&A costs down by $1.4 million
- Cash runway extends into 2026, covering planned IND submission for GB3226
Negative
- Low cash position of only $11.9 million
- Company will require substantial additional capital to finance operations and future clinical development
- Significant reduction in R&D spending might impact development progress
News Market Reaction
On the day this news was published, GLTO declined 3.35%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, announced its operating and financial results for the quarter ended March 31, 2025.
“During the first quarter, we continued to advance GB3226, our dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of AML,” said Dr. Hans Schambye, CEO of Galecto. “We continued preclinical studies to support our planned IND submission, which remains on track for Q1 2026. To date, preclinical data have shown significant improvement in efficacy compared to current FLT3 and menin inhibitors, with activity across a broad spectrum of patient genotypes. We believe GB3226 has the potential not only as a monotherapy but also as a powerful combination agent with existing standard of care and emerging therapies, offering new hope for patients with AML. We look forward to advancing GB3226 through IND-enabling studies and into clinical development in 2026.”
First Quarter 2025 Financial Results
Cash and cash equivalents as of March 31, 2025 were approximately
Research and development expenses were
General and administrative expenses were
Net loss attributable to common stockholders for the quarter ended March 31, 2025, was
About Galecto
Galecto is a clinical-stage biopharmaceutical company committed to realizing the promise of novel treatments for cancer and liver diseases. The Company’s pipeline consists of first-in-class small molecule drug candidates that target cancer and fibrosis signaling pathways, including (i) an orally active galectin-3 inhibitor (GB1211) for the treatment of liver cirrhosis; (ii) an orally active galectin-3 inhibitor (GB1211) in combination with a checkpoint inhibitor for various oncology indications; and (iii) a preclinical dual inhibitor of ENL-YEATS and FLT3 (BRM-1420) for multiple genetic subsets of AML. Galecto intends to use its website as a means of disclosing material non-public information. For regular updates about Galecto, visit www.galecto.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Galecto’s preclinical and clinical development plans for GB3226 and its potential to address challenging genetic subsets of AML; Galecto’s belief that GB3226 could be used as a monotherapy and in combination with other therapeutic agents, and Galecto’s expectation that its cash and cash equivalents will be sufficient to fund its operating expenses and capital requirements into 2026, including the submission of an investigational new drug application for GB3226 to the FDA. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. For such statements, Galecto claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Galecto's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include risks and uncertainties related to the development of Galecto’s product candidates and their therapeutic potential, having adequate funds and their use, and those disclosed in Galecto’s filings with the Securities and Exchange Commission (SEC), including, but not limited to, Galecto’s Annual Report on Form 10-K, as filed with the SEC on March 19, 2025, and Galecto’s Quarterly Report on Form 10-Q, as filed with the SEC on May 8, 2025. These forward-looking statements represent Galecto's judgment as of the time of this release. Galecto disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.
For more information, contact:
Investors/US
Sandya von der Weid
svonderweid@lifesciadvisors.com
+41 78 680 0538
| GALECTO, INC. Condensed Consolidated Balance Sheets (in thousands, except share and per share amounts) | |||||||
| March 31, | December 31, | ||||||
| 2025 | 2024 | ||||||
| (unaudited) | |||||||
| Cash and cash equivalents | $ | 11,939 | $ | 14,175 | |||
| Prepaid expenses and other current assets | 2,984 | 2,664 | |||||
| Operating lease right-of-use assets | 73 | 73 | |||||
| Other assets, noncurrent | 369 | 220 | |||||
| Total assets | $ | 15,365 | $ | 17,132 | |||
| Current liabilities | $ | 1,551 | $ | 1,197 | |||
| Operating lease liabilities, noncurrent | 60 | 61 | |||||
| Other liabilities, noncurrent | 45 | 43 | |||||
| Total liabilities | 1,656 | 1,301 | |||||
| Total stockholders’ equity | 13,709 | 15,831 | |||||
| Total liabilities and stockholders' equity | $ | 15,365 | $ | 17,132 | |||
| GALECTO, INC. Condensed Consolidated Statements of Operations and Comprehensive Loss (in thousands, except share and per share amounts) (unaudited) | |||||||
| For the Three Months Ended March 31, | |||||||
| 2025 | 2024 | ||||||
| Operating expenses: | |||||||
| Research and development | $ | 678 | $ | 2,463 | |||
| General and administrative | 1,921 | 3,278 | |||||
| Total operating expenses | 2,599 | 5,741 | |||||
| Loss from operations | (2,599 | ) | (5,741 | ) | |||
| Total other income, net | 68 | 264 | |||||
| Loss before income tax expense | (2,531 | ) | (5,477 | ) | |||
| Income tax expense | (2 | ) | — | ||||
| Net loss | $ | (2,533 | ) | $ | (5,477 | ) | |
| Net loss per common share, basic and diluted | $ | (1.92 | ) | $ | (5.05 | ) | |
| Weighted-average number of shares used in computing net loss per common share, basic and diluted | 1,322,011 | 1,084,509 | |||||
| Other comprehensive gain (loss), net of tax | 203 | (54 | ) | ||||
| Total comprehensive loss | $ | (2,330 | ) | $ | (5,531 | ) | |
FAQ
What is Galecto's (GLTO) cash position as of Q1 2025?
How much did Galecto (GLTO) lose in Q1 2025?
What is GB3226 and when does Galecto plan to submit its IND?
How did Galecto's operating expenses change in Q1 2025 compared to Q1 2024?
Will Galecto need additional funding for its operations?
